An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that ...
Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure ...
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory ...
Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims ...
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ...
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed ...
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen ...
RNA editing startup Airna is adding more funds to its Series A round, raising another $60 million as it develops genetic medicines for lung, cardiovascular, metabolic and blood diseases. The Boston- ...
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...
In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the ...
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results